Abstract. The dosimetry for two, similarly sized tumours in a lymphoma patient being treated with non-bone marrow ablative, monoclonal antibody therapy is reported. The 45-year-old man was infused with 2.48 GBq (67 mCi) of !31I-labelled MB-I. Prior to therapy, a time series of diagnostic conjugate-view images and a radionuclide transmission scan were obtained and processed to obtain time-activity curves. Starting 2 days after the therapeutic infusion of radioactivity, a second conjugate-view time series was obtained. At that time, a quantitative single-photon emission tomography (SPET) acquisition was also carried out. Pre-and post-therapy X-ray computed tomography scans demonstrated a percentage reduction in volume for the right tumour which was 3.8 times that for the left tumour. In contrast, diagnostic conjugate views by themselves estimated the absorbed dose to be the same for the two tumours. Addition of therapy conjugate-view data increased the rightover-left ratio but only to 1.22. Normalizing either timeactivity series by the intra-therapy SPET results increased the ratio to greater than 1.5. We assume here that a differential dose is correct according to the differential tumour shirnkage. One can further assume that the largest ratio corresponds most certainly to the most accurate dosimetric method. Other assumptions are possible. While additional study is essential, data from this patient suggest that the preferred dosimetric method is intra-therapy SPET normalization of either time series.
Introduction
Therapy of non-Hodgkin's B-cell lymphoma patients with both bone marrow ablative (Press et al. 1989; Eary et al. 1990 ) and non-bone marrow ablative (Wahl et al. 1990 ) amounts of 131I-labelled pan B-cell MB-1 monoclonal antibody (Link et al. 1986 ) is in progress. In both of these trials, the patient is initially imaged with conjugate views over days following a diagnostic administration of activity for estimation of tumour dosimetry (Eary et al. , 1990 Press et al. 1989; Wahl et al. 1990 ). However, one cannot guarantee that the pharmacokinetics after a therapeutic administration will be the same as after tracer administration. Moreover, two phantom studies indicate that quantification with single-photon emission tomography (SPET) is more accurate than with conjugate views (Bigler 1989; Doherty et al. 1985; Zanzonico et al. ] 
989).
For a lymphoma patient, we describe here absorbeddose results for two, similarly sized tumours from the predicted therapy time-activity series based on diagnostic conjugate views. We compare them with those from (1) that time series with the activities normalized by the activities from a single, intra-therapy SPET scan, (2) the time series combined with a late-starting therapy conjugate-view time series and (3) the series in (2) normalized by the SPET scan. Another possibility, use of SPET during diagnostic scanning, was not attempted because of anticipated reconstruction problems with the minimal-count data. Note that our basic quantitative SPET approach has been validated with an anthropomorphic phantom as being accurate within + 13 % (Koral et al. 1989) . We also measured reduction in volume for the two tumours. We then compared the single reduction-in-volume ratio to the four calculated radiation absorbed-dose ratios.
Case report
The patient studied was a 45-year-old man who was diagnosed with advanced-stage, follicular, mixed large and small cell lymphoma and initially treated by splenectomy and chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisone. His clinical remission lasted about 2 years, at which time widespread, progressive, bulky lymphadenopathy appeared. A biopsy revealed the tumour to be reactive with MB-1, and the patient was subsequently referred for entry into a Food and Drug Administration (FDA) and IRB approved study of 131I-labelled MB-I therapy.
Diagnosis.
After informed consent, quantitative planar imaging of the patient using a conjugate-view method was performed at 2, 24, 48, 72, 96 and 120h post-diagnostic infusion of 185 MBq (5 mCi; 40 mg) of 13~I-labetled MB-I. Briefly, the method was similar to that of Doherty et al. (1985) and proceeded as follows. Two calibration curves were determined. One gave transmission versus effective thickness and was obtained with a 57Co disc source and a water bath containing various thicknesses of water. The other yielded camera efficiency (geometric mean counts/MBq) as a function of effective thickness. It was determined by imaging a known activity source of 131I centered in various thicknesses of water. A 57Co transmission scan of the patient was taken to determine the effective thickness in the region of the tumour. Tumour regions of interest (ROIs) were drawn on the anterior and posterior emission images as well as background ROIs adjacent to the tumour. The tumour geometric mean count was obtained by subtracting the background and taking the mean. From it and the efficiency corresponding to the effective thickness, the value for each point on the time-activity curves shown in the top panel of Fig. 1 was obtained.
Therapy. Next, 2 days after the therapeutic infusion of 2.48 GBq (67 mCi; 40 mg) of 13~I-labelled MB-I, a therapy conjugate-view time series was carried out from 2 to 5 days. At 2 days, a quantitative SPET acquisition was also made with a GE 400 AT gammacamera plus high-energy collimator, 128 stops and a 21.33-rain imaging time.
To enable SPET Compton scatter correction by the dual-energy window method, we employed a 20% photopeak window (nominal setting: 327-400 keV) and a scatter window of the same width (254-326 keV). Before reconstruction, an approximate correction for camera deadtime was also made. For 99mTc we found that correction by combining the count rates from the two windows and computing a single paralysable model deadtime appears to be acceptable ). For 131I in a phantom, monitor-source measurements with the direct window yielded a deadtime of 15.0 gs. For the patient, from the direct-window count rate and this deadtime, the paralysable model estimated the deadtime correction factor to be 1.12. We approximated the desired single deadtime correction factor by this value and multiplied both projection sets by it. After deadtime correction, the scatter projections were subtracted from the photopeak projections using a scatter multiplier ("k" value) of 0.75 (Koral et al. 1990 b) .
The resultant SPET data were reconstructed by an iterative expecation maximization (EM) algorithm using an independently determined attenuation map and yielding a maximum likelihood (ML) solution (Tsui et al. 1989) . Convergence of activity values is obtained after sixteen iterations of this programme. Attenuation maps were extracted from an X-ray computed tomography (CT) scan. The technique involves first reconstructing with no attenuation correction to locate registration landmarks, then superim- The dose difference between the right and left tumor with normalization agreed better with the post-therapy volume reduction actually observed by CT, assuming that absorbed dose is proportional to the extent of tumor shrinkage posing attenuation maps and finally reconstructing again employing attenuation correction based on the maps. The attenuation coefficients at each pixel were extrapolated in energy from 70 keV (the "effective" energy of the CT scan) to 364 keV (Nickoloff et al. 1981) . The superimposition was achieved by a shifting and scaling computer programme which utilized the centers (x, y and z) of the two tumours in both modalities as input. One of the resultant images is shown in Fig. 2 . A needed SPET camera efficiency measurement for 1311 was made using the method detailed previously (Koral et al. 1990a ). Absolute tumour activities were then obtained from (1) this efficiency and (2) the counts in ROI determined by a semi-automated, second-derivative, edge-detection programme. The resultant SPET activities in percentage of decay-corrected administered activity for the left and right tumours are shown by two points in the bottom panel of Fig. 1 .
Tumour volumes. Initial tumour volumes for dosimetry were determined from the CT scan taken 8 days before therapy. The patient also had a follow-up CT scan 34 days after therapy, from which post-therapy volumes and reductions in volume were calculated.
Dose calculation.
The time-activity data points were fitted by a bi-exponential (see curves in top panel of Fig. 1 ). From this fit, the dependence of absolute therapy activity on time was calculated. Integrating the function for this dependence from zero to infinity gave the cumulated activity. The SPET-normalized version of a curve was obtained by multiplying each activity by a tumour-specific constant which is chosen so as to allow the normalized curve to pass through the SPET-determined activity. These normalized curves are shown in the bottom panel of Fig. 1. (They, of course, yielded different cumulated activities.)
To use the therapy conjugate-view time series, early points had to be estimated. These were obtained from the early part of the diagnostic series by normalization so that agreement existed at day 2 (the start of the therapy series). Then, bi-exponential fitting yielded a third set of cumulated activities. The final set was calculated by normalizing the combined diagnostic and therapy time series by the SPET results. The radiation absorbed self-dose for each tumour was found from the respective cumulated activity by our implementation of Medical Internal Radiation Dose (MIRD) committee methods (Koral et al. 1989) .
Results and discussion
The pre-treatment volume from all pertinent CT slices for the right tumour was 29.6 cm 3 and for the left, 22.6 cm a. After therapy, the percentage reduction in this volume (the ratio of the difference pre-treatment volume minus post-treatment volume over pre-treatment volume times 100) was 66.9% for the right and 17.6% for the left tumour. That is, the percentage reduction for the right tumour was 3.8 times that for the left.
Absolute values of predicted activities were lower with therapy conjugate views than with diagnostic ones for both tumours. As for curve shape, the time to peak increased about 53% during therapy compared with diagnosis for both tumours. The activity washed out of the right tumour 37% faster during therapy (diagnostic time minus therapy time divided by diagnostic time) but 16% slower for the left (therapy time minus diagnostic time divided by diagnostic time). With therapy conjugate views, our time from peak to half-peak for a 40-rag protein dose can be compared with that for a groin tumour with a 55-mg protein dose (Eary et al. 1990 ). The average of right, 51.3 h, and left, 36.3 h, is 44 h, exactly equal to the measurement.
The effect of the SPET deadtime correction was to increase the calculated activities by 15%. Importantly, as seen in Fig. 1 , SPET normalization tended to separate the time-activity curves pertaining to the left and right tumours.
The resultant radiation-absorbed dose values for all four procedures are shown in Table 1 . It is seen that the right-over-left absorbed-dose ratio is 1.00 with diagnostic conjugate views alone. It increases to 1.22 with the combination of diagnostic and therapy conjugate views possibly due to differences in pharmacokinetics. With intra-therapy SPET normalization of either of the two, the ratio jumps to greater than 1.5 possibly reflecting increased accuracy with SPET. We assume a dose ratio greater than 1.0 is correct because the tumour shrinkage ratio is greater than 1.0. The proportionality constant of the assumed relationship between shrinkage ratio and dose ratio is not known, however. In addition, there are errors in the four calculated dose ratios which we assume are somewhat comparable. We then tentatively conclude that the largest dose ratio corresponds most probably to the most accurate dosimetric method: intra-therapy SPET normalization of either conjugateview time series.
Above, we have assumed that tumour volume reduction serves as a good index of radiation dose. However, tumour volume regression may not reflect clonogenic cell kill, which is presumably coupled to dose. Interphase cell killing (of clonogenic and non-clonogenic cells) has been adduced as a possible mechanism to explain the apparent cell loss at relatively low radiation dose in lymphoma; the non-clonogenic cell kill may differentially affect tumours of the same size, leading to variable cell loss and hence volume reduction for the same clonogenic cell kill. A superior radiation dose index might be the time taken for tumour regrowth (Kallman 1987), but it is not available for this patient.
